Journal
INFLAMMATION AND REGENERATION
Volume 39, Issue 1, Pages -Publisher
BMC
DOI: 10.1186/s41232-019-0107-z
Keywords
Liver cirrhosis; Acute on chronic; Mesenchymal stem cell; Cell therapy
Categories
Funding
- Ministry of Education, Science, Technology, Sports, and Culture of Japan [18K07903]
- [17fk0210101h0001]
- Grants-in-Aid for Scientific Research [18K07903] Funding Source: KAKEN
Ask authors/readers for more resources
Mesenchymal stem cells (MSCs) can be cultured relatively easily and can be obtained not only from the bone marrow, but also from medical waste such as adipose tissue and umbilical cord tissue. Because of its low antigenicity, allogeneic MSC injection is safe. MSCs have been evaluated in more than 900 clinical trials in a variety of fields, with more than 50 clinical trials related to liver diseases. Experiments have suggested that MSCs function as conducting cells to affect various effective cells such as T cells, B cells, and macrophages. Recent clinical trials have focused on allogeneic MSCs. Thus, studies are needed to determine the most effective cell source, culture conditions, cell numbers, administration frequency, administration route, cost, safety, and liver disease treatments. Recently, the functions of exosomes have gained attention, and cell-free therapy may become possible as an alternative therapy for liver disease. In this review, we introduce general information, mechanism, representative clinical study data, recently started or planned clinical trials, and possibility of cell-free therapy of MSCs.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available